(Reuters) – At least 10 different drug compounds ranging from cancer therapies to antipsychotics and antihistamines may be effective at preventing the new coronavirus from multiplying in the body, according to a multidisciplinary study conducted by a team of scientists in the United States and France.
FILE PHOTO: A computer image created by Nexu Science Communication together with Trinity College in Dublin, shows a model structurally representative of a betacoronavirus which is the type of virus linked to COVID-19, better known as the coronavirus linked to the Wuhan outbreak, shared with Reuters on February 18, 2020. NEXU Science Communication/via REUTERS
People wear masks as they walk past a closed beach during the outbreak of the coronavirus disease (COVID-19) in Del Mar, California, U.S., April 30, 2020. REUTERS/Mike Blake
(Reuters) – The U.S. Centers for Disease Control and Prevention (CDC) on Thursday reported 1,031,659 cases of new coronavirus, an increase of 26,512 cases from its previous count, and said the number of deaths had risen by 2,552 to 60,057.
The CDC reported its tally of cases of the respiratory illness known as COVID-19, caused by a new coronavirus, as of 4 p.m. ET on April 29, compared with its count a day earlier. (bit.ly/2IVY1JT)
Temple University Hospital is now participating in a variety of clinical trials that are testing investigational treatment options for patients diagnosed with the novel coronavirus, or COVID-19.
COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While many COVID-19 patients will experience mild to moderate respiratory illness and recover, others will face lung injury, acute respiratory distress syndrome (ARDS), and even death.
At the Temple Lung Center, we have always been committed to research and to providing our patients with access to the latest treatment options that are available for their particular condition. That remains true for those diagnosed with COVID-19, a devastating virus that we continue to learn more about with each passing day.”
A new observational study by a group of scientists explores the rise in the public’s fear-driven interest in unproven therapies for COVID-19, particularly chloroquine and hydroxychloroquine, by tracking the internet searches relating to the purchase of drugs in news reports or publicized by public figures. They conclude: “Stay grounded in evidence and fight misinformation.” The research letter and accompanying editorial comment are published in the journal JAMA Internal Medicine.
(Reuters) – The top U.S. infectious disease official said Gilead Sciences Inc’s experimental antiviral drug remdesivir will become the standard of care for COVID-19 after early results from a key clinical trial on Wednesday showed it helped patients recover more quickly from the illness caused by the coronavirus.
Preliminary results from a U.S. government trial showing that patients given remdesivir recovered 31% faster than those given a placebo, were hailed by Dr. Anthony Fauci as “highly significant.”
“This is really quite important,” Fauci told reporters at the White House, likening it to a moment in 1986 “when we were struggling for drugs for HIV and we had nothing.”
WASHINGTON (Reuters) – U.S. President Donald Trump on Wednesday greeted as good news reports that a Gilead Sciences Inc experimental antiviral drug might help fight the coronavirus, and infectious disease official Anthony Fauci said data shows it appears to help patients hospitalized with COVID-19.
Fauci, though, told reporters during a White House meeting with Trump that the data on the drug, remdesivir, needs to be further analyzed.
Some trial data for the drug will likely be announced later on Wednesday at a White House task force briefing, according to the National Institute of Allergy and Infectious Diseases.
Last month, after California Gov. Gavin Newsom ordered most of the state’s residents to stay home, I found myself under virtual house arrest with an uncomfortably large number of Gen Zers.
Somehow I had accumulated four of my children’s friends over the preceding months. I suppose some parents more hard-nosed than I would have sent them packing, but I didn’t have the heart — especially in the case of my daughter’s college roommate, who couldn’t get back to her family in Vietnam.
The Critical Path Institute (C-Path) today announced that its Type 1 Diabetes (T1D) Consortium has received a letter of support from the European Medicines Agency (EMA) to facilitate the development and validation of the proposed regulatory qualification of pancreatic islet autoantibodies commonly used in clinical practice to diagnose T1D: insulin autoantibodies, glutamic acid decarboxylase 65, and insulinoma antigen-2 autoantibodies as enrichment biomarkers for T1D clinical trials.
In their response to the T1D Consortium Letter of Intent (LOI) and Briefing Package, the EMA stated, “[Therapies that preserve endogenous β-cell function and can prevent, halt or slow T1D disease progression in a clinically meaningful way would constitute a significant advancement in T1D care.
SACRAMENTO — During the first week of school closures in San Jose, state Sen. Jim Beall’s office received more than a dozen phone calls from distressed parents and caregivers.
The problem: They couldn’t get free lunches because school district rules required children be present to receive a meal. A grandmother caring for at least seven children couldn’t fit them all in her car. One parent had a sick child who needed to stay at home, and another was unable to bring her child, who has disabilities, to wait in the drive-thru lunch line.